Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

96.98 +3.26 (+3.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,069,756
Open 95.88
Bid (Size) 92.00 (1)
Ask (Size) 98.00 (2)
Prev. Close 93.72
Today's Range 94.98 - 97.44
52wk Range 36.90 - 98.82
Shares Outstanding 120,757,877
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter 2024 Results on May 9
From Natera, Inc.
Via Business Wire

Performance

YTD
+56.62%
+56.62%
1 Month
+5.00%
+5.00%
3 Month
+40.92%
+40.92%
6 Month
+125.01%
+125.01%
1 Year
+79.26%
+79.26%

More News

Read More
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
From Natera, Inc.
Via Business Wire
Looking Into Natera's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Natera
Via Benzinga
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
From Natera, Inc.
Via Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
From Natera, Inc.
Via Business Wire
Looking Into Natera's Recent Short Interest
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
Via Investor Brand Network
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
Recap: Natera Q4 Earnings
Via Benzinga
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
From Natera, Inc.
Via Business Wire
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
From Natera, Inc.
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
From Natera, Inc.
Via Business Wire
Agilent Technologies Stock Getting Closer To Key Technical Benchmark
Via Investor's Business Daily
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Natera to Participate in March Investor Conferences
From Natera, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
Earnings Scheduled For February 28, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.